Document is current

Article History

Received: 12 February 2024

Accepted: 12 December 2024

First Online: 28 December 2024

Declarations

:

: A. Grünewaldt reports personal fees from Boehringer Ingelheim for lectures and GSK for consultancy during advisory board meetings. G. Rohde reports personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for consultancy during advisory board meetings, furthermore personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures. M. Gaillard reports no competing interests.

: The study protocol was endorsed by the local ethics committee of the university hospital, Goethe university Frankfurt (study number 22-785).